But one of the rarest muscular disorders is also one of the most concerning. It's called myasthenia gravis and affects only about 37 out of every 100,000 people in the United States. Despite being ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

Medications for myasthenia gravis (MG) can include cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, and antibody fragment medications. While myasthenia gravis ...

The Neuromuscular Disease Center has a long history of providing excellent clinical care and research in myasthenia gravis. Myasthenia gravis is a chronic autoimmune disorder that causes muscle ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

KFDA approves Argenxs Vibgart for severe myasthenia gravis treatment KFDA greenlights innovative therapy for muscle weakness ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...